Global Premenstrual Dysphoric Disorder Market, By Treatment (Antidepressants, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Analgesics, Hormone Therapy, Exercise, Diet, Others), Diagnosis (Physical Examination, Others), Symptoms (Depression, Intense Anger, Mood Swings, Irritability, No interest in your usual activities, Anxiety, Trouble Concentrating, Appetite Changes, Feeling out of control, Fatigue, Cramps and Bloating, Tension, Headache, Insomnia, Joint or Muscle Pain, Breast Tenderness, Hot Flashes, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Global Premenstrual Dysphoric Disorder Market Analysis and Size
The rise in premenstrual dysphoric disorder and rising healthcare expenditure are the major factors influencing the market growth rate. Furthermore, advancement in medical technology, growing government funding and increasing initiatives by public and private organizations to spread awareness about the disease and its preventive options are the factors that will expand the global premenstrual dysphoric disorder market.
Data Bridge Market Research analyses that the global premenstrual dysphoric disorder market was USD 326.40 million in 2022, is expected to reach USD 436.49 million by 2030, and is expected to undergo a CAGR of 3.7% during the forecast period 2023-2030. This indicates that the market value. “antidepressants” dominates the treatment segment of the global premenstrual dysphoric disorder market owing to rising prevalence of the premenstrual dysphoric disorder. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Premenstrual Dysphoric Disorder Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Antidepressants, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Analgesics, Hormone Therapy, Exercise, Diet, Others), Diagnosis (Physical Examination, Others), Symptoms (Depression, Intense Anger, Mood Swings, Irritability, No interest in your usual activities, Anxiety, Trouble Concentrating, Appetite Changes, Feeling out of control, Fatigue, Cramps and Bloating, Tension, Headache, Insomnia, Joint or Muscle Pain, Breast Tenderness, Hot Flashes, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Bristol-Myers Squibb Company(U.S.), Merck Sharp & Dohme Corp.(U.S.), Novartis AG (Switzerland), Cipla Inc. (India), GlaxoSmithKline plc (U.K), Teva Pharmaceutical Industries Ltd.(Isreal), Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited(U.S.), Sanofi (France), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd.(India), Apotex Inc.(Canada), Mylan N.V.(U.S.), Allergan(Ireland), Takeda Pharmaceutical Company Limited.(Japan), Sumitomo Dainippon Pharma Co., Ltd.(Japan), Dr. Reddy’s Laboratories Ltd.(India), and Lupin, Bausch Health Companies Inc (india)
|
|
Market Opportunities
|
|
Market Definition
PMDD is a condition similar to PMS that occurs a week or two before your period begins as hormone levels drop after ovulation. PMDD is associated with more severe symptoms than PMS, such as depression, irritability, and tension. PMDD has an unknown aetiology. It could be a reaction to the usual hormonal changes that occur during each menstrual cycle. The hormone changes can produce a serotonin deficiency. Serotonin is a chemical found naturally in the brain and intestines that narrows blood vessels and can impact mood and induce physical symptoms
Global Premenstrual Dysphoric Disorder Market Dynamics
Drivers
- Rising Incidence
There is evidence to suggest that PMDD is becoming more prevalent, or at least more recognized and diagnosed. This increase in incidence drives the demand for treatments and therapies.
- Advances in Research
Ongoing research into the causes and mechanisms of PMDD is leading to the development of new treatment options. Understanding the underlying biology of PMDD can open doors to more targeted therapies.
- Lifestyle Changes
Changing lifestyles, including increased stress levels, poor dietary habits, and reduced physical activity, can exacerbate PMDD symptoms. This may lead to a greater demand for both pharmaceutical and non-pharmaceutical interventions.
Opportunities
- Innovative Therapies
The development of novel therapeutic approaches specifically targeting PMDD can create significant opportunities. This includes both pharmaceuticals and non-pharmaceutical treatments, such as cognitive-behavioral therapy (CBT), lifestyle interventions, and dietary supplements.
- Personalized Medicine
Advancements in genomics and personalized medicine can lead to the identification of genetic markers or biomarkers associated with PMDD. Tailoring treatments to individual genetic profiles could improve the effectiveness of interventions and enhance patient outcomes.
Restraints/Challenges
- Diagnostic Challenges
Diagnosing PMDD can be challenging due to the subjective nature of symptoms and the absence of specific biomarkers. This can result in misdiagnosis or delayed diagnosis.
- Lack of Standardized Treatment Guidelines
There is a lack of universally accepted treatment guidelines for PMDD, which can lead to variations in treatment approaches and outcomes. This can make it difficult for healthcare providers to determine the most effective interventions.
This global premenstrual dysphoric disorder market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global premenstrual dysphoric disorder market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Premenstrual Dysphoric Disorder Market Scope
The global premenstrual dysphoric disorder market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Antidepressants
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Analgesics
- Hormone Therapy
- Exercise
- Diet
- Others
Diagnosis
- Physical Examination
- Others
Symptoms
- Depression
- Intense Anger
- Mood Swings
- Irritability
- No interest in your usual activities
- Anxiety, Trouble Concentrating
- Appetite Changes
- Feeling out of control
- Fatigue
- Cramps and Bloating
- Tension
- Headache
- Insomnia
- Joint or Muscle Pain
- Breast Tenderness
- Hot Flashes
- Others
Dosage
- Tablet
- Injection
- Others
Route of Administration
- Oral
- Intravenous
- Others
End-Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Premenstrual Dysphoric Disorder Market Regional Analysis/Insights
The global premenstrual dysphoric disorder market is analysed and market size insights and trends are provided by country, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global Premenstrual Dysphoric Disorder Market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global premenstrual dysphoric disorder market because of the strong base of healthcare facilities, strong presence of major players in the market, rising prevalence of the global premenstrual dysphoric disorder and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The global premenstrual dysphoric disorder market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global premenstrual dysphoric disorder market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global premenstrual dysphoric disorder market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Premenstrual Dysphoric Disorder Market Share Analysis
The global premenstrual dysphoric disorder market competitive landscape provides details by competitor. details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. the above data points provided are only related to the companies' focus related to global premenstrual dysphoric disorder market.
Some of the major players operating in the global premenstrual dysphoric disorder market are:
- Pfizer Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Merck Sharp & Dohme Corp. (U.S.)
- Novartis AG (Switzerland)
- Cipla Inc. (India)
- GlaxoSmithKline plc (U.K)
- Teva Pharmaceutical Industries Ltd. (Isreal)
- Eli Lilly and Company (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sanofi (France)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Apotex Inc. (Canada)
- Mylan N.V. (U.S.)
- Allergan(Ireland)
- Takeda Pharmaceutical Company Limited. (Japan)
- Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Dr. Reddy’s Laboratories Ltd. (India)
- Lupin, Bausch Health Companies Inc (India)
SKU-